Future Science Group
Browse

sorry, we can't preview this file

...but you can still download Supplementary file A.docx
Supplementary file A.docx (416.09 kB)

Supplementary file A: Effectiveness of bisoprolol versus other beta-blockers and other antihypertensive classes: a cohort study in the CPRD.docx

Download (416.09 kB)
dataset
posted on 2022-02-22, 09:55 authored by Caroline Foch, Arthur Allignol, Thilo Hohenberger, Emmanuelle Boutmy, Stephan Schaefer, Ulrike Hostalek

Supplementary Appendix A

Supplementary Table 1. Antihypertensive drugs considered for each treatment of interest.

Supplementary Figure 1. A model showing the progress of each patient through different hypertension states over time.

Supplementary Figure 2. Patient attrition and the number of patients in each analysis set.

Supplementary Table 2. Baseline characteristics before matching, in patients fulfilling the study criteria.

Supplementary Table 3. Baseline comorbidities and comedications, in patients fulfilling the study definition.

Supplementary Figure 3. Distribution of the propensity scores, after matching.

Supplementary Table 4. Baseline characteristics of all analysis sets, post-matching.

Supplementary Figure 3. Distribution of the propensity scores, after matching.

Supplementary Table 5. Standardized mean differences before/after matching.

Supplementary Table 6. Transition intensities for the multi-state model between controlled and uncontrolled BP states, length of stay in the controlled state, after matching in the BP analysis set.

Supplementary Table 7. Number of events and safety event incidence rates after matching, for each event of interest and comparison group.

Supplementary Table 8. Cause-specific Cox proportional hazards models and Fine and Gray models for T2DM – sensitivity analysis excluding patients with prior impaired fasting blood glucose levels.

Supplementary Table 9. Cause-specific Cox proportional hazards models and Fine and Gray models for competing events of outcome for interest.

Funding

Fully funded by Merck KGaA (CrossRef Funder ID: 10.13039/100009945)

History